Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotorasib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
sotorasib + chemotherapy is a combination therapy regimen developed by Amgen for the treatment of advanced solid tumors characterized by the KRAS G12C mutation. This therapeutic approach combines sotorasib (AMG 510), a first-in-class small molecule that selectively and irreversibly binds to the KRAS G12C protein in its inactive GDP-bound state, with various standard-of-care chemotherapy agents. The chemotherapy components evaluated in clinical trials like CodeBreaK 101 include platinum-based agents (carboplatin, oxaliplatin), antimetabolites (5-fluorouracil, pemetrexed), taxanes (docetaxel, paclitaxel), and topoisomerase inhibitors (irinotecan). By combining targeted KRAS G12C inhibition with the broad cytotoxic effects of chemotherapy, the regimen aims to enhance anti-tumor efficacy, achieve deeper responses, and delay the emergence of resistance in patients with KRAS G12C-mutated cancers such as non-small cell lung cancer and colorectal cancer.
- Brand names
- Lumakras + chemotherapy
- Other names
- sotorasib plus chemotherapyAMG 510 plus chemotherapyAMG510 plus chemotherapyAMG-510 plus chemotherapy
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on sotorasib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotorasib + chemotherapy.